astrazeneca glp 1 AZ to terminate once-daily cotadutide program to focus on weekly GLP-1RA co-agonist AstraZeneca Advances Elecoglipron to Phase

Those with a BMI of 35 or over may be eligible for bariatric surgery covered by Medicare

Lau D, Claudius B, Skjth TV, Bjrn Jensen C, P.H

Safety The most frequently reported side effects of GLP-1RAs are of gastrointestinal (GI) origin, including nausea, vomiting, diarrhoea and obstipation and may be more common in patients with higher age, lower body weight, renal impairment, and if there is a history or currently smoking (75)

We estimate that roughly half of people affected by obesity in the US will be eligible to benefit from GLP-1s overall, around 50 million people

So the argument to be made is using the lowest GLP-1 dose possible to elicit gradual weight loss over time while optimizing diet, resistance exercise, etc